Blood Flow
Conditions
Keywords
Gut hormones, GIP, Physiology, Type 2 diabetes
Brief summary
This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with type 2 diabetes.
Detailed description
Each participant will attend four independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo) and oral ingestion (glucose/water): An intravenous infusion of saline or GIP(3-30)NH2 starts at time point -20 minutes.The infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes on two of the experimental days (with and without GIP(3-30)NH2). MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines, pancreas, and bones.
Interventions
OTHERSaline / placebo
NaCl (9 mg/ml)
GIP(3-30)NH2
Sponsors
University of Copenhagen
Rigshospitalet, Denmark
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Intervention model description
Single blind, placebo controlled, randomized, crossover study
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes * BMI 20-35 kg/m\^2 * Age 20-80
Exclusion criteria
* Not MRI-compatible implants * Claustrophobia * Abnormal kidney or liver function * Anemia * Planned weight loss or change in diet * Hypertension * Other conditions that could be expected to affect the primary or secondary outcomes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Redistribution of splanchnic blood flow in the vessel mesenteric superior artery (functional MRI) | 80 minutes | Measued with phase-contrast MRI in ml/min |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GIP levels | 80 minutes | Radioimmuno assay on plasma blood sample (pmol/L) |
| GIP(3-30)NH2 levels | 80 minutes | Radioimmuno assay on plasma blood sample (nmol/L) |
| C-peptide | 80 minutes | Electrochemiluminescence immunoassay of plasma blood sample (pmol/L) |
| Insulin | 80 minutes | Electrochemiluminescence immunoassay of plasma blood sample (pmol/L) |
| Glucagon | 80 minutes | Radioimmuno assay on plasma blood samples (pmol/L) |
| Blood flow in portal vein | 80 minutes | Measued with phase-contrast MRI in ml/min |
| Blood flow in coeliac trunc | 80 minutes | Measued with phase-contrast MRI in ml/min |
| Glucose | 80 minutes | Bedside measurement of whole blood sample (mmol/L) |
| Blood flow in hepatic artery | 80 minutes | Measued with phase-contrast MRI in ml/min |
Countries
Denmark
Outcome results
None listed